Search Results - "Mateos, Maria"

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study by Dimopoulos, Meletios, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Yang, Hui, Klippel, Zandra, Zahlten-Kumeli, Anita, Usmani, Saad Z

“…Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma…”
Get full text

Multiple myeloma: patient outcomes in real‐world practice by Yong, Kwee, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Raab, Marc S., Schoen, Paul, Cavo, Michele

“…Summary With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We…”
Get full text

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial by Dimopoulos, Meletios A, Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M, Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, Carson, Robin, Sonneveld, Pieter, Alegre Amor, Adrian, Baldini, Luca, Beksac, Meral, Belotti, Angelo, Benboubker, Lotfi, Besemer, Britta, Besisik, Sevgi, Bila, Jelena, Boccadoro, Mario, Cavo, Michele, De La Rubia Comos, Javier, Delimpasi, Sosana, Dimopoulos, Meletios A., Doyen, Chantal, Dytfeld, Dominik, Engelhardt, Monika, Facon, Thierry, Foà, Roberto, Goldschmidt, Hartmut, Grosicki, Sebastian, Hajek, Roman, Hayri Ozsan, Guner, Hulin, Cyrille, Iversen, Brian, Karlin, Lionel, Katodritou, Eirini, Knop, Stefan, Kyrtsonis, Marie-Christine, Lahuerta, Juan Jose, Leleu, Xavier, Martinez Chamorro, Carmen, Mateos Manteca, María-Victoria, Meuleman, Nathalie, Minnema, Monique, Moreau, Philippe, Offidani, Massino, Oriol Rocafiguera, Albert, Pehlivan, Mustafa, Pour, Ludek, Roerdink, Henk Th.J., Rosinol Dacsh, Laura, Salwender, Hans, Sonneveld, Pieter, Symeonidis, Anargyros, Toftmann Hansen, Charlotte, Tuglular, Tulin, Unal, Ali, Vlummens, Philip, Vural, Filiz, Wu, Ka Lung, Zweegman, Sonja

“…In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well…”
Get full text

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set by Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Avet-Loiseau, Hervé

“…The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to…”
Get full text

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial by Mateos, María-Victoria, Oriol, Albert, Martínez-López, Joaquín, Gutiérrez, Norma, Teruel, Ana-Isabel, López de la Guía, Ana, López, Javier, Bengoechea, Enrique, Pérez, Montserrat, Polo, Marta, Palomera, Luis, de Arriba, Felipe, González, Yolanda, Hernández, Jose-Mariano, Granell, Miquel, Bello, José-Luis, Bargay, Joan, Peñalver, Francisco-Javier, Ribera, José-María, Martín-Mateos, María-Luisa, García-Sanz, Ramón, Lahuerta, Juan-José, Bladé, Joan, San-Miguel, Jesús F.

“…Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant in elderly patients because the major benefit results from the…”
Get full text

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? by Mateos, María-Victoria, Oriol, Albert, Martínez-López, Joaquín, Teruel, Ana-Isabel, López de la Guía, Ana, López, Javier, Bengoechea, Enrique, Pérez, Montserrat, Martínez, Rafael, Palomera, Luis, de Arriba, Felipe, González, Yolanda, Hernández, José Mariano, Granell, Miquel, Bello, José-Luis, Bargay, Joan, Peñalver, Francisco-Javier, Martín-Mateos, María-Luisa, Paiva, Bruno, Montalbán, María-Angeles, Bladé, Joan, Lahuerta, Juan-Jose, San-Miguel, Jesús F.

“…Melphalan (M), in combination with prednisone (MP), has been the backbone of new combinations, including bortezomib plus MP (VMP). However, new alkylator-free…”
Get full text

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial by Mateos, Maria-Victoria, Cavo, Michele, Blade, Joan, Dimopoulos, Meletios A, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Krevvata, Maria, Chen, Ying, Wang, Jianping, Kudva, Anupa, Ukropec, Jon, Wroblewski, Susan, Qi, Ming, Kobos, Rachel, San-Miguel, Jesus

“…Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous…”
Get full text

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group by Sonneveld, Pieter, Avet-Loiseau, Hervé, Lonial, Sagar, Usmani, Saad, Siegel, David, Anderson, Kenneth C., Chng, Wee-Joo, Moreau, Philippe, Attal, Michel, Kyle, Robert A., Caers, Jo, Hillengass, Jens, San Miguel, Jesús, van de Donk, Niels W.C.J., Einsele, Hermann, Bladé, Joan, Durie, Brian G.M., Goldschmidt, Hartmut, Mateos, María-Victoria, Palumbo, Antonio, Orlowski, Robert

“…The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic…”
Get full text

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis by Kastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, María Teresa, Kwok, Fiona, Mollee, Peter, Hájek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schönland, Stefan O, Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, María-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A, Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Johnsen, Hans Erik, Merlini, Giampaolo, Palladini, Giovanni

“…Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been…”
Get full text

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network by Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, Sonneveld, Pieter

“…T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse…”
Get full text

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth by Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, Richardson, Paul

“…Summary The randomized phase III ELOQUENT‐2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus…”
Get full text

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE by San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, Bahlis, Nizar J.

“…In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA…”
Get full text

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents by Cohen, Adam D., Mateos, María-Victoria, Cohen, Yael C., Rodriguez-Otero, Paula, Paiva, Bruno, van de Donk, Niels W. C. J., Martin, Thomas, Suvannasankha, Attaya, De Braganca, Kevin C., Corsale, Christina, Schecter, Jordan M., Varsos, Helen, Deraedt, William, Wang, Liwei, Vogel, Martin, Roccia, Tito, Xu, Xiaoying, Mistry, Pankaj, Zudaire, Enrique, Akram, Muhammad, Nesheiwat, Tonia, Pacaud, Lida, Avivi, Irit, San-Miguel, Jesus

“…•Cilta-cel, a BCMA-targeting chimeric antigen receptor−T-cell therapy, induced clinical responses in patients previously exposed to noncellular anti-BCMA…”
Get full text

Teclistamab in Relapsed or Refractory Multiple Myeloma by Moreau, Philippe, Garfall, Alfred L., van de Donk, Niels W.C.J., Nahi, Hareth, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun X.W., Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, Krishnan, Amrita, Usmani, Saad Z.

“…In this phase 1–2 study involving patients with relapsed or refractory myeloma, a bispecific antibody (teclistamab) that mediates T-cell activation and…”
Get full text

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma by Martinez-Lopez, Joaquin, Lahuerta, Juan J., Pepin, François, González, Marcos, Barrio, Santiago, Ayala, Rosa, Puig, Noemí, Montalban, María A., Paiva, Bruno, Weng, Li, Jiménez, Cristina, Sopena, María, Moorhead, Martin, Cedena, Teresa, Rapado, Immaculada, Mateos, María Victoria, Rosiñol, Laura, Oriol, Albert, Blanchard, María J., Martínez, Rafael, Bladé, Joan, San Miguel, Jesús, Faham, Malek, García-Sanz, Ramón

“…We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow…”
Get full text

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study by Usmani, Saad Z, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Gavriatopoulou, Maria, Oriol, Albert, Rabin, Neil, Nooka, Ajay, Qi, Ming, Beksac, Meral, Jakubowiak, Andrzej, Ding, Bifeng, Zahlten-Kumeli, Anita, Yusuf, Akeem, Dimopoulos, Meletios

“…Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory multiple myeloma, especially in…”
Get full text

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma by SAN-MIGUEL, Jesús F, RICHARDSON, Paul G, SONG MU, BOURQUELOT, Priscille M, MATEOS, Maria Victoria, ANDERSON, Kenneth C, GÜNTHER, Andreas, SEZER, Orhan, SIEGEL, David, BLADE, Joan, LEBLANC, Richard, SUTHERLAND, Heather, SOPALA, Monika, MISHRA, Kaushal K

“…Despite advancements, prognosis for patients with relapsed/refractory multiple myeloma (MM) is poor, and novel therapies are needed. Panobinostat is a potent…”
Get full text

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma by Lonial, Sagar, Dimopoulos, Meletios, Palumbo, Antonio, White, Darrell, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Moreau, Philippe, Mateos, Maria-Victoria, Magen, Hila, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z, Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Wu, Ka Lung, Singhal, Anil, San-Miguel, Jesus, Matsumoto, Morio, Katz, Jessica, Bleickardt, Eric, Poulart, Valerie, Anderson, Kenneth C, Richardson, Paul

“…The addition of elotuzumab (a monoclonal antibody against SLAMF7) to lenalidomide plus dexamethasone produced a significant increase in progression-free…”
Get full text

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma by Richardson, Paul G, Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W, Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S, Anderson, Kenneth C, Laubach, Jacob P, Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Mateos, María-Victoria

“…Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating…”
Get full text

How I treat triple‐class refractory multiple myeloma by Costa, Luciano J., Hungria, Vania, Mohty, Mohamad, Mateos, Maria‐Victoria

“…Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38 monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM)…”
Get full text